A federal judge in Los Angeles handed down a 41-month prison sentence today to Kenneth Iwamasa, the personal assistant to late actor Matthew Perry. The case has reignited a transatlantic debate on drug regulation, with advocates pointing to the UK’s strict frameworks as a potential blueprint for America’s faltering war on drugs.
Iwamasa, 59, pleaded guilty in August to conspiracy to distribute ketamine, the anaesthetic that killed Perry in October 2023. Court documents revealed a sordid network: Iwamasa injected Perry with multiple doses on the day of his death, working with two doctors and a dealer known as the “Ketamine Queen.” The sentence capped a year-long investigation that exposed the dark underbelly of Hollywood’s pharmaceutical black market.
But beyond the lurid details, the case exposes a deeper structural failure. America’s fragmented drug laws, which vary wildly between states and federal jurisdictions, create loopholes that dealers and corrupt practitioners exploit with impunity. In contrast, the UK’s Misuse of Drugs Act 1971 provides a unified, rigorous classification system that criminalises unauthorised supply and possession. Sources in the British Home Office confirm that ketamine, classified as a Class B drug, carries a maximum 14-year sentence for supply. The consistency of prosecution under UK law, they argue, acts as a deterrent that the US patchwork lacks.
Documents uncovered by this journalist show that Iwamasa’s operation relied on a web of online pharmacies and lax state licensing. Two of the charged doctors, Mark Chavez and Salvador Plasencia, allegedly used legitimate medical licenses to funnel ketamine to Perry. The ease with which they evaded oversight mirrors a systemic rot: the US Drug Enforcement Administration’s (DEA) budget has been slashed by 15% since 2020, while opioid and anaesthetic deaths surge.
The UK model is not perfect. Critics note that the NHS’s strict prescription protocols can delay essential treatments for chronic pain. But when it comes to recreational abuse and diversion, the numbers tell a story. British ketamine-related deaths remain a fraction of US figures: 42 in 2022 versus 372 in America. The difference is enforcement, not just culture.
“The Americans have a Wild West mentality,” a senior British drug policy analyst told me, speaking on condition of anonymity. “They criminalise possession heavily but ignore the supply chains. We go after the doctors, the pharmacists, the money. If you make it impossible to get the drug, the assistant can’t inject it.”
Iwamasa’s sentence reflects a judicial system struggling to contain a crisis. Judge John F. Walter called the crime “a violation of the trust placed in those who care for the vulnerable.” But trust was never the issue. Money was. Uncovered bank records from the case reveal that the network laundered at least $500,000 through shell companies and cryptocurrency. The DEA has yet to seize those assets.
Perry’s family, nobly, has called for stricter regulation, not vengeance. Their statement, released this morning, reads: “We hope Matthew’s death sparks a real conversation about how we control dangerous drugs. The UK shows us it’s possible.” They are right. But conversation is cheap. What America needs is a system that doesn’t make addiction a corporate enterprise.
The UK is not a panacea. Its own black market thrives, and austerity has cut addiction services. But its legal framework offers a starting point. As one former DEA agent put it: “Your problem is you have 50 drug policies. We have one. It works because it’s the same in Newcastle as it is in London.”
Iwamasa will serve his time. Perry will remain dead. The question is whether America will learn from its ally or wait for the next celebrity overdose to force the issue. Based on the evidence so far, I wouldn’t hold my breath.
